Hepatitis B in Ghana: A Silent Epidemic Lurking in the Shadows
The revelation that approximately 3 million Ghanaians are living with chronic hepatitis B—with deaths rising from 15,443 in 2024 to an estimated 16,000 in 2025—has exposed a silent epidemic ravaging communities largely unnoticed. With only one per cent of cases diagnosed, this viral time bomb threatens to overwhelm Ghana’s healthcare system.
Hepatitis B is a viral infection that attacks the liver and is transmitted through contact with infected blood, semen, or other body fluids. The virus causes both acute and chronic disease, with chronic infection leading to cirrhosis, liver failure, and hepatocellular carcinoma. In Ghana, the prevalence rate ranges between 8% and 12% in the general population, classifying the country as highly endemic.
The true scale of the crisis is only now becoming clear. Data from the Ghana Health Service indicates that more than 500,000 people are infected, yet only about 20,000 patients are currently receiving treatment—a treatment gap of over 95%. Without intervention, most of the 3 million infected individuals will progress to liver disease or death within the next two decades, significantly increasing the national cost of care.
Compounding this crisis is the alarming prevalence among pregnant women, with studies showing rates between 6.7% and 12.6%. Mother‑to‑child transmission remains a major driver of new infections, as Ghana’s hepatitis B birth‑dose vaccination programme has only recently been scaled up. Additionally, the country records approximately 2,200 new cases of liver cancer annually, the majority linked to chronic hepatitis B infection. Late‑stage survival rates are extremely low—less than 5% at five years.
The economic burden is equally severe. The World Health Organization estimates that hepatitis B‑related liver disease and cancer cost Ghana more than $100 million annually in direct medical expenses and lost productivity. In response, the government has secured a significant reduction in treatment costs through the Global Fund’s Pooled Procurement Mechanism, bringing the annual cost per patient down to roughly $48.
Based on these findings, health authorities are calling for a multi‑pronged approach: mass screening campaigns to identify the undiagnosed 99%, accelerated childhood vaccination, expanded access to antiviral therapy, and robust public education to combat stigma and encourage testing.
Effective control of hepatitis B could save more than 10,000 lives annually, prevent 50,000 new infections each year, and free millions from the threat of liver cancer and cirrhosis—protecting both Ghana’s public health and its economic future.